Guardant’s Cancer Blood Test Matches Tissue Biopsies in Trial

A large-scale study comparing Guardant Health Inc.’s blood test to tissue biopsies showed that results were closely matched. The findings may help doctors feel more confident in using the blood test as a non-invasive alternative to traditional biopsies, according to the startup.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.